Plain-English translation of NCT04960826 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are investigating whether a naturally occurring toxin called deoxynivalenol (DON)—found in some grains and foods—might be an environmental trigger for inflammatory bowel disease, particularly Crohn's disease. The study will analyze tissue samples from people with Crohn's disease and from people undergoing intestinal surgery for other reasons (like cancer or polyps) to understand how the body processes this toxin and how it affects the gut bacteria and immune system. By comparing these two groups, researchers hope to uncover whether DON exposure plays a role in disease development.
Inflammatory bowel disease develops from a complex combination of genetics, gut bacteria, and environmental factors that scientists still don't fully understand. This study aims to identify whether everyday environmental exposures—specifically this food-related toxin—may be a missing piece of the puzzle, which could eventually lead to new ways to prevent or treat the disease.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would provide tissue samples during your planned surgery—these are collected as part of the surgical procedure itself and do not require additional invasive steps. Researchers will analyze these samples to measure how your body processes the toxin and how it affects your gut bacteria and immune system. The study compares findings between people with Crohn's disease and those undergoing surgery for other reasons to identify potential environmental risk factors.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
France
Sponsor
University Hospital, Lille
Collaborators
National Research Agency, France
Enrollment target
~100 participants
Started
September 2021
Primary completion
July 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
25 Years – 60 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Philippe ZERBIB, MD,PhD
University Hospital, Lille
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.